Tharimmune Inc. (THAR) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Tharimmune Inc. (THAR:NASDAQ), powered by AI.

Current Price
$3.30
P/E Ratio
-2.9
Market Cap
106M
Sector
Healthcare
What is the Tharimmune Inc. stock price forecast?

Tharimmune Inc. is currently trading at $3.30. View real-time AI analysis on Alpha Lenz.

What is Tharimmune Inc. insider trading activity?

View the latest insider trading data for Tharimmune Inc. on Alpha Lenz.

What is Tharimmune Inc.'s P/E ratio?

Tharimmune Inc.'s P/E ratio is -2.9.

Tharimmune Inc.

NASDAQ · THAR
$3.30+0.09(+2.80%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Tharimmune Inc.'s future dividend policy...
Alpha Chat Insight

Tharimmune Inc. trades at a P/E of -2.9 (undervalued) with modest ROE of -18.0%.

Ask for details

Company Overview

Tharimmune Inc. is a biotechnology company focused on the development and commercialization of innovative immunotherapies. The company's core purpose is to address unmet medical needs by leveraging cutting-edge research in immunology to create therapies that harness the body's immune system to fight diseases, particularly in the field of oncology and autoimmune disorders. Tharimmune Inc. applies advanced technologies such as monoclonal antibodies and novel biologics in its development pipeline. By operating at the intersection of science and healthcare, the company contributes significantly to the biopharmaceutical industry, driving forward cures and treatments that can transform patient outcomes. As a player in the biotechnology sector, Tharimmune is known for its rigorous research approach and strategic partnerships, which are pivotal in advancing both clinical trials and market approval of its products. The company's commitment to innovation positions it as a vital contributor to the broader healthcare landscape, with potential impacts on patient health and treatment paradigms worldwide. Tharimmune's advancements in immunotherapies underscore its pivotal role in the dynamic and evolving pharmaceuticals market.

CEOMr. Sireesh Appajosyula Pharm.D.
SectorHealthcare
IndustryBiotechnology
Employees2

Company Statistics

FY 2025

Profile

$105.76MMarket Cap
$0.00Revenue
0.00Shares Out
2Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-2.94P/E
0.27P/B
N/AEV/Sales
-2.11EV/EBITDA
-1.13P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-13.74%ROA
-17.99%ROE
-16.09%ROIC

Financial Health

$17.03MCash & Cash Equivalents
$104.19MNet Debt
30.46%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Tharimmune Inc. (ticker: THAR) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 2 employees. Market cap is $106M.

The current price is $3.3 with a P/E ratio of -2.94x and P/B of 0.27x.

ROE is -17.99%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Tharimmune Inc. (THAR) Stock Forecast 2026 $3.30 — Price, Financials & Analyst Targets | Alpha Lenz